World of DTC Marketing
AUGUST 18, 2022
Millennium Pharma’s ad and website for ENTYVIO touch all the bases with targeted patients. It shows that the team understands what it’s like for patients with severe ulcerative colitis. This is the kind of DTC that can help patients seek treatment. Empathy. Understanding what it’s like to live with health problems is the key to developing great DTC.
MedCity News
AUGUST 18, 2022
Motivo, an online platform connecting aspiring therapists with clinical supervisors, recently closed a $14 million Series A funding round. The platform, which has clinical supervisors who are licensed in all 50 states, has already helped more than 2,500 therapists obtain their licensure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medgadget
AUGUST 18, 2022
Scientists at Linköping University in Sweden have developed a collagen-based corneal implant that can restore sight to blind patients with corneal disease. The breakthrough could pave the way for such patients to receive effective treatment for corneal disease without requiring a corneal transplant from a human donor. There is a shortage of donor corneas, so creating an off-the-shelf alternative could be very useful.
MedCity News
AUGUST 18, 2022
There are high levels of substance use and dangerous mental health stigma among healthcare workers, according to a report released by addiction treatment organization APN. Its CEO said the most effective way to decrease stigma about seeking mental health treatment is to look at healthcare as inclusive of mental health.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Clarivate
AUGUST 18, 2022
From today, we’re pleased to announce that Web of Science Researcher Profiles is improved with new features for tracking your publications, citation metrics, peer reviews and journal editing, all in one place – making it the one-stop destination for managing your academic profile and demonstrating your expertise. We have created the next generation of the Web of Science Researcher Profiles by incorporating the best features of Publons and ResearcherID.
PharmaVoice
AUGUST 18, 2022
Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Medico Reach
AUGUST 18, 2022
The healthcare sector has seen a few developments over the years. However, nothing has been more impactful on the industry than the advent of digital health. Wondering what that is? Well, it’s simple: It’s the use of communication and information technologies to improve existing medical practices. In fact, studies have found that the global market share for digital health will go beyond $430.5 billion in 2022.
MedCity News
AUGUST 18, 2022
Developing the mental health infrastructure needed to treat mental illnesses in a coordinated and preventive manner, reducing risks before they reach a crisis point, will require a multi-stakeholder approach.
Pharmaceutical Technology
AUGUST 18, 2022
Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The approach of Atomwise makes the process of drug discovery more logical and efficient by moving away from serendipitous discovery and toward a search that is structure-based.
MedCity News
AUGUST 18, 2022
Surgery management has emerged as a key area where employers are collaborating with providers through companies like Transcarent to provide more informed guidance on surgery care delivery options for the best patient outcomes and experience.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
AUGUST 18, 2022
Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
MedCity News
AUGUST 18, 2022
While the lymphoma study is now clear to resume enrolling patients, the status of a partial hold on a separate leukemia study remains unchanged so far. The partial holds were placed on both studies of the Curis cancer drug after a patient death in the leukemia trial.
European Pharmaceutical Review
AUGUST 18, 2022
Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the agreement, Merck will make an upfront payment to Orna of $150 million.
MedCity News
AUGUST 18, 2022
The company, created by the founder of Zocdoc, is focused on providing low-cost and sometimes no-cost care. Currently, it only offers prescriptions for Covid-19 antivirals.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Medgadget
AUGUST 18, 2022
Scientists from McGill University in Canada created a technique of using ultrasound-mediated cavitation to make bioadhesives better stick to body’s tissues, including wet surfaces that are typically challenging for such materials. The new method involves ultrasound to create microbubbles within the adhesive. The bubbles burst, which then temporarily forces some of the adhesive components deeper into the underlying tissue, helping to create a stronger bond.
MedCity News
AUGUST 18, 2022
The industry average of customer satisfaction reached 809 on a 1,000-point scale in 2022, up three points from 2021 and up 15 points over the last five years.
pharmaphorum
AUGUST 18, 2022
Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that includes an offer to settle outstanding lawsuits. The Ireland-domiciled company is struggling under the weight of around $8 billion in debt, and has been hamstrung by costs associated with fighting thousands of suits that accuse it of wrongdoing in its marketing and promotion of painkiller Opana ER (oxymorphon
MedCity News
AUGUST 18, 2022
“This decision sends pharmacists a dangerous message: you’re expected to overrule doctors – and not doing so can be costly.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
AUGUST 18, 2022
As Frontiers Health approaches, we’re featuring interviews with members of the steering committee to give you a sneak peek of what to expect in Milan. Interested in signing up? pharmaphorum readers get a discount through this link. Though the field is still young, digital therapeutics are no longer a brand-new technology. Many different DTx offerings are in the field, being used by patients and prescribed by physicians, backed by rigorous scientific evidence.
Map My Customers
AUGUST 18, 2022
If you are only measuring your sales reps’ performance by revenue, then you are missing the point. Of course, revenue-based sales metrics will tell you if your team is meeting sales quotas or not. But, they’re not going to provide an explanation as to exactly why they are or they aren’t. And that is truly the most valuable information to have if you want your team to be successful and continue to be successful moving forward.
Copyright Clearance Center
AUGUST 18, 2022
The post Leveraging Semantics for Effective Navigation of Scientific Content appeared first on Copyright Clearance Center.
PharmaTimes
AUGUST 18, 2022
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Teachntest
AUGUST 18, 2022
9 Important Copper T Side Effects The Copper T (Copper IUD) is a small, T-shaped piece of copper and soft plastic that is inserted into the uterus. The Copper T (Copper IUD) contains copper but no hormones. How it works? IUDs stop sperm from fusing with eggs. One of the most reliable methods of birth […].
pharmaphorum
AUGUST 18, 2022
Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-3 (NK3) receptor antagonist fezolinetant. The US regulator is scheduled to complete its review of fezolinetant as a treatment for moderate to severe vasomotor symptoms (VMS) of menopause, such as hot flushes and night sweats, by 22 February next year, said the Japanese pharma.
PharmExec
AUGUST 18, 2022
Raj Verma, chief diversity, culture, and experience officer at Sanofi, discusses the various ways people see diversity around the world and how companies should be building diversity, equity, and inclusion into a company’s everyday fabric.
pharmaphorum
AUGUST 18, 2022
UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos – which will be launched in the next few weeks. CSL Vifor – which licenses Tavneos (avacopan) from US biotech ChemoCentryx – announced the decision on behalf Vifor Fresenius Medical Care Renal Pharma, its joint venture with Fresenius, which will market the drug in the UK.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
AUGUST 18, 2022
New Zealand’s Medsafe has granted expanded provisional approval for Novavax ’s protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster dose in adults aged 18 years and above. The booster vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group. With the approval, people could opt to receive Nuvaxovid as their first and/or second booster dose(s) for Covid-19 following the conclusion of the initial vaccine re
pharmaphorum
AUGUST 18, 2022
Researchers also dove into socio-economic disparities in cancer care. Last month in Chicago, Illinois the American Society of Clinical Oncology hosted its first in-person meeting since the COVID-19 pandemic began. In presentations and published abstracts, researchers shared a massive amount of data across all cancer types and treatment modalities. Below are just a few of the highlights from the show.
Copyright Clearance Center
AUGUST 18, 2022
The post New Features In CCC Marketplace Help Publishers Engage With Leading Medical Communications Professionals appeared first on Copyright Clearance Center.
pharmaphorum
AUGUST 18, 2022
bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the prici
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
197 
Let's personalize your content